Inaugural Advisory Board Includes Internationally Renowned Experts In Oncology and Radiation Therapy BOSTON, MA and HAMILTON, ONTARIO, July 16, 2018 – Fusion…
Read More
BOSTON, MA and HAMILTON, ONTARIO, April 27, 2018 – Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics (specifically, targeted alpha therapeutics), announced…
Technology will be used to progress Fusion’s pipeline of targeted alpha therapeutics for the treatment of cancers Cambridge, UK and…
HAMILTON, ONTARIO – At the 2018 LSO Annual Awards Presentation event, Fusion Pharmaceuticals was awarded “Life Sciences Company of the Year.” The award recognizes Fusion as an outstanding company which contributed...
Read More
BOSTON, MA and HAMILTON, ONTARIO, February 21, 2018 – Fusion Pharmaceuticals, a biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today…
TORONTO– LSO today announced the recipients of its 2018 LSO Awards, recognizing outstanding individuals and companies contributing to the success…
HAMILTON, ONTARIO, September 25, 2017 – Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced it…
HAMILTON ONTARIO, February 23, 2017 – Fusion Pharmaceuticals, a newly formed biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer,…
Image-guided medicines for hard to treat cancers built using next generation medical isotopes TORONTO, ON (December 16, 2015) – FACIT…
HAMILTON, ONT. — 05/01/16 — Fusion Pharmaceuticals, Inc. (“Fusion”), a life sciences company focused on developing novel drugs for the…
